Literature DB >> 19386274

Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.

Yuki Takahashi1, Makiya Nishikawa, Yoshinobu Takakura.   

Abstract

RNA interference (RNAi) is a potent and specific gene silencing event in which small interfering RNA (siRNA) degrades target mRNA. Therefore, RNAi is of potential use as a therapeutic approach for the treatment of a variety of diseases in which aberrant expression of mRNA causes a problem. RNAi can be achieved by delivering siRNA or vectors that transcribe siRNA or short-hairpin RNA (shRNA). The aim of this review is to examine the potential of nonviral vector-mediated RNAi technology in treating diseases. The characteristics of plasmid DNA expressing shRNA were compared with those of siRNA, focusing on the duration of gene silencing, delivery to target cells and target specificity. Recent progresses in prolonging the RNAi effect, improving the delivery to target cells and increasing the specificity of RNAi in vivo are also reviewed.

Mesh:

Substances:

Year:  2009        PMID: 19386274     DOI: 10.1016/j.addr.2009.04.006

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  30 in total

1.  Use of siRNA in knocking down of dopamine receptors, a possible therapeutic option in neuropsychiatric disorders.

Authors:  Mohammad-Reza Noori-Daloii; Majid Mojarrad; Ali Rashidi-Nezhad; Majid Kheirollahi; Ali Shahbazi; Mehdi Khaksari; Asghar Korzebor; Ali Goodarzi; Maryam Ebrahimi; Ali Reza Noori-Daloii
Journal:  Mol Biol Rep       Date:  2011-06-03       Impact factor: 2.316

Review 2.  Delivery of siRNA therapeutics: barriers and carriers.

Authors:  Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-06-11       Impact factor: 4.009

Review 3.  Polymeric nucleic acid carriers: current issues and novel design approaches.

Authors:  Han Chang Kang; Kang Moo Huh; You Han Bae
Journal:  J Control Release       Date:  2012-07-04       Impact factor: 9.776

Review 4.  Cell- and gene-based therapeutic strategies for periodontal regenerative medicine.

Authors:  Hector F Rios; Zhao Lin; Bina Oh; Chan Ho Park; William V Giannobile
Journal:  J Periodontol       Date:  2011-02-02       Impact factor: 6.993

Review 5.  New short interfering RNA-based therapies for glomerulonephritis.

Authors:  Hideki Shimizu; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2011-05-24       Impact factor: 28.314

Review 6.  Remedial applications of silencing ribonucleic acids and modalities for its delivery to the kidneys--a review.

Authors:  Dongjie Wang; Yanfen Lv; Huifang Zhu; Guifeng Lv; Jiyi Huang
Journal:  Afr J Tradit Complement Altern Med       Date:  2014-06-04

7.  Characterization and evaluation of a peptide-based siRNA delivery system in vitro.

Authors:  Baoling Chen; Kimoon Yoo; Wen Xu; Ran Pan; Xiao Xia Han; P Chen
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

Review 8.  Gene electrotransfer: from biophysical mechanisms to in vivo applications : Part 2 - In vivo developments and present clinical applications.

Authors:  Jean-Michel Escoffre; Chloé Mauroy; Thomas Portet; Luc Wasungu; Aurelie Paganin-Gioanni; Muriel Golzio; Justin Teissié; Marie-Pierre Rols
Journal:  Biophys Rev       Date:  2009-11-10

9.  Drug delivery systems: Advanced technologies potentially applicable in personalized treatments.

Authors:  Jorge F Coelho; Paula C Ferreira; Patricia Alves; Rosemeyre Cordeiro; Ana C Fonseca; Joana R Góis; Maria H Gil
Journal:  EPMA J       Date:  2010-04-10       Impact factor: 6.543

10.  Efficient inhibition of lung cancer in murine model by plasmid-encoding VEGF short hairpin RNA in combination with low-dose DDP.

Authors:  Yong P Ma; Yang Yang; Shuang Zhang; Xiang Chen; Na Zhang; Wei Wang; Zhi X Cao; Yu Jiang; Xia Zhao; Yu Q Wei; Hong X Deng
Journal:  J Exp Clin Cancer Res       Date:  2010-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.